Australia · Delayed Price · Currency is AUD Chimeric Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Shareholders approved major capital raising resolutions, a share consolidation, and discussed governance, capital allocation, and operational shifts to Australia. Key challenges included low retail participation, historical losses, and ASX compliance.
-
Two core cell therapy assets are advancing through late phase I, with strong manufacturing success and promising early clinical outcomes. Regulatory milestones and commercial interest are building, while industry trends show renewed momentum in cell therapy. Key updates on Dose Level 3 and further trial progress are expected soon.
Fiscal Year 2025
-
Phase 1 trials for two cell therapy assets show strong safety, tumor shrinkage, and durable responses, with CHM CDH17 nearing Phase 2 and CHM CORN-K achieving over 50% response rates in AML. Commercial interest and regulatory progress are advancing, with key milestones expected in FY26.
-
CHM 2101, a first-in-class CDH17 CAR-T therapy, is showing promising safety and early anti-tumor activity in phase one trials, with eight patients treated and no off-target effects observed. Fast track status and strong investigator enthusiasm support rapid development and commercial potential.
-
The meeting covered major fundraising achievements, clinical trial progress, and significant cost reductions. All resolutions, including share and option issuances, were overwhelmingly supported by proxies, with final results to be released to the ASX.
-
Active clinical trials are progressing, with promising early results in both CAR-T and NK cell programs. Financial stability has improved following recent capital raises, enabling continued patient recruitment and data generation. Regulatory and operational challenges persist, but strong partnerships and a lean, expert team support ongoing progress.
-
Significant clinical progress was reported for two cell therapy platforms, with early human data showing safety and disease stabilization in solid and blood cancers. Financially, new funding supports ongoing trials, and strategic focus is on advancing CHM CDH17 and CORE-NK, with partnership discussions underway.